205 related articles for article (PubMed ID: 33535732)
1. Risk of tuberculosis is increased in Behçet’s disease compared to other rheumatological disorders after anti-TNFα treatments: a case series and review of the literature.
Gazel Ü; Kocakaya D; Hicret Topçu İ; Ömer Karataş H; Karabacak M; Atagündüz MP; İnanç GN; Alibaz Öner F; Direskeneli RH
Turk J Med Sci; 2021 Aug; 51(4):1689-1694. PubMed ID: 33535732
[TBL] [Abstract][Full Text] [Related]
2. The T-SPOT.TB assay used for screening and monitoring of latent tuberculosis infection in patients with Behçet's disease pre- and post-anti-TNF treatment: A retrospective study.
Shen Y; Ma HF; Luo D; Guan JL
J Chin Med Assoc; 2019 May; 82(5):375-380. PubMed ID: 30896580
[TBL] [Abstract][Full Text] [Related]
3. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
[TBL] [Abstract][Full Text] [Related]
4. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
[TBL] [Abstract][Full Text] [Related]
5. Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?
Kilic O; Kasapcopur O; Camcioglu Y; Cokugras H; Arisoy N; Akcakaya N
Rheumatol Int; 2012 Sep; 32(9):2675-9. PubMed ID: 21789614
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment.
Borekci S; Atahan E; Demir Yilmaz D; Mazıcan N; Duman B; Ozguler Y; Musellim B; Hamuryudan V; Ongen G
Respiration; 2015; 90(3):191-8. PubMed ID: 26137891
[TBL] [Abstract][Full Text] [Related]
7. QuantiFERON®-TB Gold In-Tube test can be used for screening latent tuberculosis before biological treatment in a Bacille Calmette-Guérin (BCG)-vaccinated country: the HUR-BIO single-center real-life results.
Seyhoglu E; Uyaroğlu OA; Erden A; Kilic L; Karadag O; Akdogan A; Bilgen SA; Ertenli I; Kiraz S; Kalyoncu U
Clin Rheumatol; 2021 May; 40(5):2027-2035. PubMed ID: 33057917
[TBL] [Abstract][Full Text] [Related]
8. Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet's disease in Taiwan.
Hu YC; Yang YH; Lin YT; Wang LC; Yu HH; Lee JH; Chiang BL
BMC Pediatr; 2019 Jul; 19(1):232. PubMed ID: 31296171
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of the interferon-γ release assay for tuberculosis infection in patients with Behçet's disease.
Wu X; Chen P; Wei W; Zhou M; Li C; Liu J; Zhao L; Zhang L; Zhao Y; Zeng X; Liu X; Zheng W
BMC Infect Dis; 2019 Apr; 19(1):323. PubMed ID: 30987605
[TBL] [Abstract][Full Text] [Related]
10. TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.
Sargın G; Şentürk T; Ceylan E; Telli M; Çildağ S; Doğan H
Tuberk Toraks; 2018 Jun; 66(2):136-143. PubMed ID: 30246657
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
[TBL] [Abstract][Full Text] [Related]
12. A population-based study of tuberculosis incidence among rheumatic disease patients under anti-TNF treatment.
Sartori NS; Picon P; Papke A; Neyeloff JL; da Silva Chakr RM
PLoS One; 2019; 14(12):e0224963. PubMed ID: 31790428
[TBL] [Abstract][Full Text] [Related]
13. Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.
Garziera G; Morsch ALB; Otesbelgue F; Staub FL; Palominos PE; Brenol CV; Silva DR
Clin Rheumatol; 2017 Aug; 36(8):1891-1896. PubMed ID: 28589321
[TBL] [Abstract][Full Text] [Related]
14. How many patients with rheumatic diseases and TNF inhibitors treatment have latent tuberculosis?
Busquets-Pérez N; Ponce A; Ortiz-Santamaria V; de Agustín de Oro J; Hernández-Rico YL; Vidal I; Alfonso C; Argemí S; Muñoz B; Quispe F; Díaz AC; Campos S; Hernández TM; Torres M; Surís X
Reumatol Clin; 2017; 13(5):282-286. PubMed ID: 27394672
[TBL] [Abstract][Full Text] [Related]
15. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening.
Jauregui-Amezaga A; Turon F; Ordás I; Gallego M; Feu F; Ricart E; Panés J
J Crohns Colitis; 2013 Apr; 7(3):208-12. PubMed ID: 22677117
[TBL] [Abstract][Full Text] [Related]
16. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial.
Park JH; Seo GY; Lee JS; Kim TH; Yoo DH
J Rheumatol; 2009 Oct; 36(10):2158-63. PubMed ID: 19723901
[TBL] [Abstract][Full Text] [Related]
17. Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.
Ozguler Y; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Borekci S; Atahan E; Ongen G; Hamuryudan V
Rheumatol Int; 2016 Dec; 36(12):1719-1725. PubMed ID: 27699578
[TBL] [Abstract][Full Text] [Related]
18. Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis.
Kurt OK; Kurt B; Talay F; Tug T; Soy M; Bes C; Hayran M
Wien Klin Wochenschr; 2013 Oct; 125(19-20):616-20. PubMed ID: 24061693
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk.
Cagatay T; Bingol Z; Kıyan E; Yegin Z; Okumus G; Arseven O; Erkan F; Gulbaran Z; Erelel M; Ece T; Cagatay P; Kılıçaslan Z
Clin Respir J; 2018 Apr; 12(4):1668-1675. PubMed ID: 29028148
[TBL] [Abstract][Full Text] [Related]
20. Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.
Malaviya AN; Kapoor S; Garg S; Rawat R; Shankar S; Nagpal S; Khanna D; Furst DE
J Rheumatol; 2009 Jul; 36(7):1414-20. PubMed ID: 19487263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
